Access the full text.
Sign up today, get DeepDyve free for 14 days.
Y. Murciano-Goroff, A. Warner, J. Wolchok (2020)
The future of cancer immunotherapy: microenvironment-targeting combinationsCell Research, 30
John Thompson (2018)
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.Journal of the National Comprehensive Cancer Network : JNCCN, 16 5S
P. Spallarossa, M. Sarocchi, G. Tini, E. Arboscello, M. Toma, P. Ameri, I. Porto (2020)
How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor TherapyFrontiers in Pharmacology, 11
Rushin Patel, Rohan Parikh, K. Gunturu, R. Tariq, S. Dani, Sarju Ganatra, A. Nohria (2021)
Cardiotoxicity of Immune Checkpoint InhibitorsCurrent Oncology Reports, 23
S. Ederhy, I. Benhamou-Tarallo, M. Chauvet-Droit, P. Nhan, R. Cohen, Bruno Pinna, C. Cholet, C. Fenioux, S. Champiat, J. Salem, L. Soulat-Dufour, A. Cohen (2020)
Cardiotoxicity Related to Immune Checkpoint InhibitorsCurrent Treatment Options in Cardiovascular Medicine, 23
Sireesha Upadhrasta, Hadi Elias, Keval Patel, Lei Zheng (2019)
Managing cardiotoxicity associated with immune checkpoint inhibitorsChronic Diseases and Translational Medicine, 5
P. Spallarossa, G. Meliota, C. Brunelli, E. Arboscello, P. Ameri, C. Dessalvi, F. Grossi, M. Deidda, D. Mele, M. Sarocchi, A. Bellodi, R. Madonna, G. Mercuro (2018)
Potential cardiac risk of immune‐checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effectsMedicinal Research Reviews, 38
J. Salem, A. Manouchehri, Melissa Moey, B. Lebrun-Vignes, L. Bastarache, A. Pariente, A. Gobert, J. Spano, J. Balko, Marc Bonaca, D. Roden, Douglas Johnson, J. Moslehi (2018)
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.The Lancet. Oncology, 19 12
A. Lyon, N. Yousaf, N. Battisti, J. Moslehi, J. Larkin (2018)
Immune checkpoint inhibitors and cardiovascular toxicity.The Lancet. Oncology, 19 9
Kuhnly (2022)
54Clinical Journal of Oncology Nursing, 26
Nicole Kuhnly, J. Coviello (2022)
Immune Checkpoint Inhibitor-Related Myocarditis: Recognition, Surveillance, and Management.Clinical journal of oncology nursing, 26 1
ABSTRACTImmune checkpoint inhibitor (ICI) therapy is a treatment modality used in many types of cancer. Immune-related adverse events are relatively common. Cardiovascular adverse events are uncommon, but carry a high mortality rate of 25–50%. They require cessation of therapy. There is currently no universal screening before initiation of ICI therapy to identify patients with cardiovascular risk. There is also no ongoing screening to identify myocarditis and treatment is driven by symptoms. This article provides a case study of a patient who developed myopericarditis and the patient's clinical course. Furthermore, it proposes surveillance for patients before and during ICI therapy to swiftly identify potential cases of myocarditis. There is currently no universal baseline screening for cardiovascular risk in patients planned for ICI therapy. A proposed baseline cardiac evaluation, as well as scheduled surveillance therapy, is outlined in this article. With further education and training, immune-related cardiac adverse events may be more promptly detected, leading to better patient outcomes.
Journal of the American Association of Nurse Practitioners – Wolters Kluwer Health
Published: Mar 30, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.